CR20210460A - Compuestos útiles en la terapia del vih - Google Patents

Compuestos útiles en la terapia del vih

Info

Publication number
CR20210460A
CR20210460A CR20210460A CR20210460A CR20210460A CR 20210460 A CR20210460 A CR 20210460A CR 20210460 A CR20210460 A CR 20210460A CR 20210460 A CR20210460 A CR 20210460A CR 20210460 A CR20210460 A CR 20210460A
Authority
CR
Costa Rica
Prior art keywords
compounds useful
hiv therapy
hiv
compounds
therapy
Prior art date
Application number
CR20210460A
Other languages
English (en)
Inventor
Emile Johann Velthuisen
David Temelkoff
La Rosa Martha Alicia De
John F Miller
B Narasimhulu Naidu
Vicente Samano
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd, Viiv Healthcare Co filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CR20210460A publication Critical patent/CR20210460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a compuestos de Fórmula (I), sales de los mismos, composiciones farmacéuticas de los mismos, así como métodos de tratamiento o prevención del VIH en sujetos.
CR20210460A 2019-03-06 2020-03-04 Compuestos útiles en la terapia del vih CR20210460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
CR20210460A true CR20210460A (es) 2022-02-03

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210460A CR20210460A (es) 2019-03-06 2020-03-04 Compuestos útiles en la terapia del vih

Country Status (21)

Country Link
US (2) US20230174534A1 (es)
EP (1) EP3934760A1 (es)
JP (1) JP2022525013A (es)
KR (1) KR20210136052A (es)
CN (1) CN113811360A (es)
AR (1) AR118240A1 (es)
AU (1) AU2020231934B2 (es)
BR (1) BR112021017604A2 (es)
CA (1) CA3132112A1 (es)
CL (1) CL2021002309A1 (es)
CO (1) CO2021012579A2 (es)
CR (1) CR20210460A (es)
EA (1) EA202192433A1 (es)
IL (1) IL285894A (es)
MA (1) MA55200A (es)
MX (1) MX2021010700A (es)
PE (1) PE20212089A1 (es)
SG (1) SG11202109253SA (es)
TW (1) TW202102233A (es)
WO (1) WO2020178767A1 (es)
ZA (1) ZA202106096B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
KR20220156884A (ko) * 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
WO2022142477A1 (en) * 2020-12-30 2022-07-07 Southern University Of Science And Technology Methods and modified nucleosides for treating coronavirus infections
CA3204255A1 (en) * 2021-01-25 2022-07-28 Lianhong Xu Combination therapy for hiv with adenosine derivative and capsid inhibitors
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR20030093248A (ko) 2001-03-19 2003-12-06 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2016057866A1 (en) * 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CN107074899A (zh) * 2014-10-31 2017-08-18 桑多斯股份公司 改进的氟化工艺
RU2720811C2 (ru) * 2015-09-23 2020-05-13 Мерк Шарп И Доум Лимитед 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
CN110325542A (zh) * 2016-11-03 2019-10-11 劳伦斯·I·吴 克罗拉滨的前体药物
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy

Also Published As

Publication number Publication date
US20230174534A1 (en) 2023-06-08
AU2020231934A8 (en) 2022-03-24
SG11202109253SA (en) 2021-09-29
AU2020231934B2 (en) 2023-04-20
CO2021012579A2 (es) 2021-10-20
CN113811360A (zh) 2021-12-17
MA55200A (fr) 2022-01-12
AU2020231934A1 (en) 2021-09-23
KR20210136052A (ko) 2021-11-16
IL285894A (en) 2021-10-31
WO2020178767A1 (en) 2020-09-10
ZA202106096B (en) 2023-03-29
MX2021010700A (es) 2021-10-01
EA202192433A1 (ru) 2021-12-28
AR118240A1 (es) 2021-09-22
TW202102233A (zh) 2021-01-16
EP3934760A1 (en) 2022-01-12
BR112021017604A2 (pt) 2021-11-16
JP2022525013A (ja) 2022-05-11
CA3132112A1 (en) 2020-09-10
PE20212089A1 (es) 2021-11-04
CL2021002309A1 (es) 2022-09-20
US20220411425A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
NZ733174A (en) Quinazoline derivatives used to treat hiv
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2021001612A (es) Compuestos utiles en terapia del vih.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
WO2018039077A8 (en) Therapeutic compounds
SG10201907289VA (en) Monomethylfumarate prodrug compositions
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2023000198A (es) Inhibidores de atr y usos de estos.